{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:45:18Z","timestamp":1780472718176,"version":"3.54.1"},"reference-count":25,"publisher":"Korean Ophthalmological Society","issue":"3","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ekjo.org"],"crossmark-restriction":true},"short-container-title":["Korean J Ophthalmol"],"published-print":{"date-parts":[[2024,6,5]]},"abstract":"<jats:p>Purpose: To assess efficacy, safety, and tolerability of the preservative-free (PF) fixed-dose combination (FC) of tafluprost 0.0015%\/timolol 0.5% (PF tafluprost\/timolol FC) in treatments-naive patients with primary open-angle glaucoma (POAG).Methods: This was a retrospective, real-world clinical practice setting study that included 107 eyes of 107 subjects with POAG who had never been treated for glaucoma. All subjects were received PF tafluprost\/timolol FC once daily. Intraocular pressure (IOP) levels were documented for each eye at the untreated baseline and up to 6 months after the initiation of medical treatment. All adverse events, including ocular and systemic adverse reactions, were recorded. Additionally, the reasons for medication discontinuations were thoroughly documented.Results: A total of 32 POAG patients with high-baseline IOP (&gt;21 mmHg) and 75 with normal-baseline IOP were included in the study. The subjects\u2019 baseline mean age was 62.4 \u00b1 8.7 years (range, 26.0\u201385.0 years); among them, 42 were female (39.3%). Mean IOP at baseline for all patients was 18.6 \u00b1 4.3 mmHg. The mean IOP at 6 months was 12.6 \u00b1 4.7 mmHg, representing a significant decrease compared to the baseline (\u201332%, &lt;i&gt;p&lt;\/i&gt; &lt; 0.001). In POAG patients with high-baseline IOP, mean IOP was significantly lowered from 28.0 \u00b1 5.7 mmHg at baseline to 18.0 \u00b1 5.5 mmHg (\u201335%, &lt;i&gt;p&lt;\/i&gt; &lt; 0.001); in patients with normal-baseline IOP, from 14.6 \u00b1 3.4 mmHg at baseline to 10.3 \u00b1 4.1 mmHg (\u201329%, &lt;i&gt;p&lt;\/i&gt; &lt; 0.001). PF tafluprost\/timolol FC was well-tolerated and safe. After 6 months, 97.2% of all patients remained on therapy.Conclusions: In this real-world observational study, once-daily treatment with PF tafluprost\/timolol FC demonstrated clinically relevant and statistically significant efficacy, as well as safety and good tolerability, in treatment-naive patients diagnosed with POAG.<\/jats:p>","DOI":"10.3341\/kjo.2024.0021","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T07:25:06Z","timestamp":1714116306000},"page":"221-226","update-policy":"https:\/\/doi.org\/10.3341\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preservative-Free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% for Treatment-Naive Patients with Open-Angle Glaucoma"],"prefix":"10.3341","volume":"38","author":[{"given":"Teakkwan","family":"Rhee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeheon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahnul","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1893","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2135701"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-egsguidelines"},{"key":"ref3","volume-title":"","author":"White","year":"2016"},{"key":"ref4","volume-title":"","year":"2016"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.6.701"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/112067210901900411"},{"key":"ref7","first-page":"716","volume-title":"Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma","author":"Baudouin","year":"2008"},{"key":"ref8","first-page":"696328","volume-title":"How ocular surface disease impacts the glaucoma treatment outcome","author":"Kastelan"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1209481"},{"key":"ref10","first-page":"350","volume-title":"Prevalence of ocular surface disease in glaucoma patients","author":"Leung","year":"2008"},{"key":"ref11","first-page":"441","volume-title":"A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma","author":"Garcia-Feijoo","year":"2012"},{"key":"ref12","first-page":"959","volume-title":"Quality of life in glaucoma: a review of the literature","author":"Quaranta","year":"2016"},{"key":"ref13","first-page":"418","volume-title":"Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication","author":"Pisella","year":"2002"},{"key":"ref14","first-page":"730","volume-title":"Preservative exposure and surgical outcomes in glaucoma patients: the PESO study","author":"Boimer","year":"2013"},{"key":"ref15","first-page":"193","volume-title":"Prescription trends for preservative free glaucoma medication in a public health system","author":"Perez-Garcia","year":"2024"},{"key":"ref16","first-page":"863","volume-title":"CCLRU grading scales (appendix D)","author":"Phillips","year":"1997"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/08164622.2021.1964331"},{"key":"ref18","first-page":"1228","volume-title":"A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components","author":"Pfeiffer","year":"2014"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0229"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s128453"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.133481"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.s264926"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s76053"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.06.012"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2008.08.004"}],"container-title":["Korean Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.ekjo.org\/upload\/pdf\/kjo-2024-0021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.ekjo.org\/journal\/view.php?doi=10.3341\/kjo.2024.0021","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.ekjo.org\/upload\/pdf\/kjo-2024-0021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T08:09:58Z","timestamp":1718093398000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ekjo.org\/journal\/view.php?doi=10.3341\/kjo.2024.0021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.3341\/kjo.2024.0021","relation":{},"ISSN":["1011-8942","2092-9382"],"issn-type":[{"value":"1011-8942","type":"print"},{"value":"2092-9382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"2024-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-26","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-05","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}